Pancreatic Cancer: Advances in Treatment and Future Prospects
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 20 July 2025 | Viewed by 249
Special Issue Editors
Interests: colorectal cancer; colorectal surgery; pancreatic cancer; pancreatic surgery; hepato-pancreato-biliary (HPB) surgery; robotic surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by an aggressive biological profile, late-stage diagnosis, and limited response to existing therapies. Despite significant advancements in our understanding of the molecular and cellular biology of PDAC, its prognosis continues to be poor, with a five-year survival rate of less than 10%. These outcomes are largely driven by the tumor’s complex biology, its propensity for early dissemination, and the challenges in achieving timely diagnosis.
Recent research has provided critical insights into the genetic and molecular landscape of PDAC, offering new opportunities for early detection and targeted therapies. Biomarkers for early diagnosis and risk stratification are an area of active exploration, with the potential to identify patients at earlier, more treatable stages of the disease. Surgical resection remains the cornerstone of curative treatment, yet it is only feasible in a minority of cases due to late-stage presentation. Advances in surgical techniques, including minimally invasive and robotic approaches, aim to optimize patient outcomes while minimizing perioperative morbidity. Moreover, managing postoperative complications, such as pancreatic fistulas, remains a key challenge in improving recovery and long-term survival.
Neoadjuvant and adjuvant therapies are increasingly being integrated into the standard of care, offering opportunities to downstage borderline resectable tumors and enhance the effectiveness of surgery. However, the optimal sequencing, combination, and personalization of these therapies are subjects of ongoing research and debate.
This Special Issue of Medicina focuses on the intersection of tumor biology, early detection, surgical innovation, and multimodal therapy in pancreatic cancer. We aim to highlight cutting-edge research and clinical advances in the following areas:
- Tumor biology and the genetic and molecular mechanisms driving PDAC progression;
- Biomarkers and novel strategies for early diagnosis and risk stratification;
- Innovations in surgical techniques, including robotic and minimally invasive approaches;
- Management and prevention of postoperative complications;
- Advances in neoadjuvant and adjuvant therapy protocols and their integration into clinical practice.
By gathering contributions from leading experts, this Special Issue seeks to provide a deeper understanding of the disease and its management, with the ultimate goal of improving early detection and optimizing therapeutic strategies to enhance patient outcomes.
Dr. Damiano Caputo
Guest Editor
Dr. Roberto Cammarata
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- pancreatic ductal adenocarcinoma (PDAC)
- biomarkers
- neoadjuvant therapy
- adjuvant therapy
- robotic surgery
- minimally invasive surgery
- precision medicine
- multidisciplinary care
- post-operative complications
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
